research Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies
Fulvestrant solution doesn't help hair loss in men and postmenopausal women.
Search
for
Sort by
Research
210-240 / 1000+ results research Forsythiaside A Activates AMP-Activated Protein Kinase and Regulates Oxidative Stress via Nrf2 Signaling
Forsythiaside A helps protect cells and liver from damage by reducing oxidative stress and boosting antioxidants.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Treatment of severe alopecia areata with oral tofacitinib: A case series
Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
research Resolution of refractory systemic lupus erythematosus-associated alopecia with anifrolumab: a case report
research Repurposing of H1-receptor antagonists (levo)cetirizine, (des)loratadine, and fexofenadine as a case study for systematic analysis of trials on clinicaltrials.gov using semi-automated processes with custom-coded software
Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
research Algorithmic approach to the treatment of frontal fibrosing alopecia: A systematic review
The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Transcriptomic characterization of Lonrf1 at the single-cell level under pathophysiological conditions
LONRF1 is important for oxidative damage response and tissue remodeling during wound healing.
research Frontal fibrosing alopecia in postmenopausal women
Some postmenopausal women with frontal fibrosing alopecia stopped losing hair with finasteride treatment, hinting at a possible hormonal cause.
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
research A retrospective study of oral tofacitinib therapy for alopecia areata
research Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Corticotropin releasing factor-1 receptor antagonism associated with favorable outcomes of male reproductive health biochemical parameters
Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
research Prospective Cohort Study on the Effects and Tolerability of Flutamide in Patients with Female Pattern Hair Loss
Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
research Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Peripheral neuropathy associated with tofacitinib use in alopecia universalis
A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
research Feronia: A malectin-like domain-containing receptor kinase in Arabidopsis thaliana insights into polarized cell growth, pollen tube - Pistil interactions, and sugar signaling
FERONIA regulates plant growth, pollen interactions, and sugar signaling.
research “Finasteride”
research Nanoliposomal Co-Delivery of AR-PROTAC and NFKBIZ siRNA for Synergistic Therapy of Androgenetic Alopecia
A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
research Frontal Fibrosing Alopecia During Treatment of Chronic Hepatitis C: A Case Report
Hepatitis C treatment may cause frontal fibrosing alopecia.
research Increasing utility of finasteride for frontal fibrosing alopecia
Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.
research Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
research <p>Frontal fibrosing alopecia: efficacy of treatment modalities</p>
Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.
research BH06 (P075) A randomized controlled trial comparing the efficacy and safety of oral tofacitinib vs. methotrexate in moderate-to-severe alopecia areata
Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.